Andre Francis Palmer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Andre Francis Palmer has a total of 293 co-authors. Here are the top co-authors by number of shared publications:
- Pedro Cabrales
University of California San Diego
22 shared publications - Ivan Susin Pires
Koch Institute for Integrative Cancer Research Massachusetts Institute of Technology 500 Main Street Cambridge MA 02139 USA
11 shared publications - Carlos Jose Munoz
Department of Bioengineering, University of California San Diego, La Jolla, CA
9 shared publications - Donald Andrew Belcher
William G. Lowrie Department of Chemical and Biomolecular Engineering The Ohio State University Columbus Ohio
9 shared publications - Quintin O'BOyle
The Ohio State University
9 shared publications Guo Chen
William G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, OH 43210
8 shared publications
Latest Publications
- Open Access
- 30 October 2026
- Published by Elsevier in Resuscitation Plus
- Vol. 32
Improving the safety and efficacy of whole blood resuscitation from hemorrhagic shock with a novel scavenger protein cocktail
- 30 October 2026
- Published by Elsevier in Resuscitation Plus
- Vol. 32
Open AccessImproving the safety and efficacy of whole blood resuscitation from hemorrhagic shock with a novel scavenger protein cocktail
- Open Access
- 9 September 2026
- Published by Elsevier in SSRN Electronic Journal
Molecular Size-Dependent Effects of Polymerized Hemoglobin on Blood Rheology and Microvascular Perfusion
Background: Hemoglobin-based oxygen carriers (HBOCs) could provide an alternative to blood transfusion when donor blood is unavailable, but clinical translation has been limited by vasoactivity and impaired microvascular perfusion. We investigated how polymerized hemoglobin (PolyhHb) molecular size influences blood rheology, microvascular perfusion, and organ injury following hemorrhagic shock resuscitation. Methods: Human hemoglobin (hHb; 64.5 kDa) and four PolyhHb formulations (1078–1569 kDa) were evaluated using flow-sweep rheology, oscillatory shear analysis, red blood cell aggregation, and Quemada modeling. Male Golden Syrian hamsters subjected to 50% blood-volume hemorrhage were randomly assigned to resuscitation with hHb or one of four PolyhHb formulations, followed by systemic, microvascular, and organ-injury assessment for 60 min. Findings: Increasing PolyhHb molecular size reduced blood storage and complex moduli but increased red blood cell aggregation. PolyhHb-12 (1200 kDa) provided the most favorable microvascular recovery, with significantly greater flow in arterioles >60 µm at 60 min than PolyhHb-10 (P<0.001), PolyhHb-15 (P<0.01), and PolyhHb-16 (P<0.0001). Compared with PolyhHb-16, the absolute difference was 2.98 nL/s (95% CI 1.47–4.48). Functional capillary density did not significantly differ among treatment groups. All PolyhHb formulations produced lower renal, cardiac, hepatic, hemolytic, and inflammatory injury biomarkers than hHb. Interpretation: PolyhHb molecular size determines a trade-off between hemorheological behavior, microvascular transport, and tissue compatibility. An intermediate molecular size provided the most favorable balance between microvascular recovery and organ protection, supporting molecular size as a critical design parameter for next-generation HBOCs.
- 9 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessMolecular Size-Dependent Effects of Polymerized Hemoglobin on Blood Rheology and Microvascular Perfusion
Background: Hemoglobin-based oxygen carriers (HBOCs) could provide an alternative to blood transfusion when donor blood is unavailable, but clinical translation has been limited by vasoactivity and impaired microvascular perfusion. We investigated how polymerized hemoglobin (PolyhHb) molecular size influences blood rheology, microvascular perfusion, and organ injury following hemorrhagic shock resuscitation. Methods: Human hemoglobin (hHb; 64.5 kDa) and four PolyhHb formulations (1078–1569 kDa) were evaluated using flow-sweep rheology, oscillatory shear analysis, red blood cell aggregation, and Quemada modeling. Male Golden Syrian hamsters subjected to 50% blood-volume hemorrhage were randomly assigned to resuscitation with hHb or one of four PolyhHb formulations, followed by systemic, microvascular, and organ-injury assessment for 60 min. Findings: Increasing PolyhHb molecular size reduced blood storage and complex moduli but increased red blood cell aggregation. PolyhHb-12 (1200 kDa) provided the most favorable microvascular recovery, with significantly greater flow in arterioles >60 µm at 60 min than PolyhHb-10 (P<0.001), PolyhHb-15 (P<0.01), and PolyhHb-16 (P<0.0001). Compared with PolyhHb-16, the absolute difference was 2.98 nL/s (95% CI 1.47–4.48). Functional capillary density did not significantly differ among treatment groups. All PolyhHb formulations produced lower renal, cardiac, hepatic, hemolytic, and inflammatory injury biomarkers than hHb. Interpretation: PolyhHb molecular size determines a trade-off between hemorheological behavior, microvascular transport, and tissue compatibility. An intermediate molecular size provided the most favorable balance between microvascular recovery and organ protection, supporting molecular size as a critical design parameter for next-generation HBOCs.
- Open Access
- 6 September 2026
- Published by Wiley in Biotechnology Progress
- p. e88555
Small scale purification and biophysical characterization of haptoglobin derived from human Cohn fraction IV
Haptoglobin (Hp) is a polymorphic acute phase α ‐2 glycoprotein found in plasma that plays a critical role in binding, neutralizing, and removing cell‐free hemoglobin (Hb) from the circulation. Under clinical conditions characterized by high levels of hemolysis, such as in patients with sickle cell disease (SCD), large quantities of cell‐free Hb are released from lysed red blood cells (RBCs) into the circulation and bind to Hp. This interaction reduces the plasma Hp concentration below basal levels and diminishes its Hb‐binding capacity. Therefore, plasma‐derived Hp has the potential to be used therapeutically to scavenge, neutralize, and remove excess cell‐free Hb from the blood, thus preventing Hb‐mediated toxicity. This provides strong motivation to purify Hp at high purity using sustainable sources, such as waste plasma fractions from the Cohn plasma fractionation process used to produce human serum albumin from pooled plasma. Starting from human Cohn fraction IV, we first enriched an Hp‐rich fraction using tangential flow filtration (TFF), which was then used as the starting material for purification. Hp was subsequently purified from this fraction using hydrophobic interaction chromatography (HIC) to homogeneity. The final Hp purity reached 98% by SDS‐PAGE densitometry and 87% by trypsin digest LC–MS/MS analysis. The purified Hp was further characterized to determine its molecular weight, secondary structure, Hb‐binding capacity, and binding kinetics using biophysical techniques including MALDI‐TOF, circular dichroism, size exclusion HPLC, and UV–visible stopped‐flow spectroscopy. More importantly, the simplicity and efficiency of the TFF–HIC workflow demonstrated strong potential for scalable Hp production.
- 6 September 2026
- Published by Wiley in Biotechnology Progress
- p. e88555
Open AccessSmall scale purification and biophysical characterization of haptoglobin derived from human Cohn fraction IV
Haptoglobin (Hp) is a polymorphic acute phase α ‐2 glycoprotein found in plasma that plays a critical role in binding, neutralizing, and removing cell‐free hemoglobin (Hb) from the circulation. Under clinical conditions characterized by high levels of hemolysis, such as in patients with sickle cell disease (SCD), large quantities of cell‐free Hb are released from lysed red blood cells (RBCs) into the circulation and bind to Hp. This interaction reduces the plasma Hp concentration below basal levels and diminishes its Hb‐binding capacity. Therefore, plasma‐derived Hp has the potential to be used therapeutically to scavenge, neutralize, and remove excess cell‐free Hb from the blood, thus preventing Hb‐mediated toxicity. This provides strong motivation to purify Hp at high purity using sustainable sources, such as waste plasma fractions from the Cohn plasma fractionation process used to produce human serum albumin from pooled plasma. Starting from human Cohn fraction IV, we first enriched an Hp‐rich fraction using tangential flow filtration (TFF), which was then used as the starting material for purification. Hp was subsequently purified from this fraction using hydrophobic interaction chromatography (HIC) to homogeneity. The final Hp purity reached 98% by SDS‐PAGE densitometry and 87% by trypsin digest LC–MS/MS analysis. The purified Hp was further characterized to determine its molecular weight, secondary structure, Hb‐binding capacity, and binding kinetics using biophysical techniques including MALDI‐TOF, circular dichroism, size exclusion HPLC, and UV–visible stopped‐flow spectroscopy. More importantly, the simplicity and efficiency of the TFF–HIC workflow demonstrated strong potential for scalable Hp production.
- Open Access
- 17 August 2026
- Published by American Chemical Society (ACS) in ACS Applied Engineering Materials
- Vol. 4 (9) , 4758-4773
Comprehensive Biophysical Characterization of Multi-Arm PEGylated Apohemoglobin as a Potential Synthetic Heme Scavenger
Cell-free heme released during hemolysis is highly toxic and pro-oxidant, necessitating the development of effective heme scavengers. In this study, four hemoglobin (Hb)-derived constructs, apohemoglobin (apoHb), linear poly(ethylene glycol) (PEG) surface conjugated apoHb (PEG-apoHb), multi-arm PEG surface conjugated apoHb (MA-PEG-apoHb), and heme-removed multi-arm PEG-Hb (HR-MA-PEG-Hb) were systematically evaluated to identify an optimal heme-scavenging candidate based on production feasibility, physicochemical characteristics, structural homogeneity, and heme-binding properties. ApoHb exhibited moderate yield (53 ± 11%), high activity (71.9 ± 7.1%), the strongest apparent ferric heme affinity (Kd,app = 10.7 ± 0.7 μM), rapid heme acquisition from heme-albumin (heme-HSA) (0.017 ± 0.0003 s−1), and fast haptoglobin (Hp) binding. However, its small hydrodynamic diameter (∼3.9 nm) suggests rapid renal clearance, limiting its potential therapeutic utility. PEG-apoHb exhibited the highest yield (82 ± 6%) and increased hydrodynamic size (10.3 ± 0.4 nm), but reduced heme-binding activity, slower heme acquisition, weaker ferric heme affinity (Kd,app = 12.6 ± 0.7 μM), accelerated heme transfer to hemopexin, and markedly diminished Hp binding. In contrast, both MA-PEG-apoHb and HR-MA-PEG-Hb exhibited larger hydrodynamic diameters (18.8 ± 1.1 and 12.1 ± 0.7 nm, respectively), reduced Hp-binding kinetics, efficient heme acquisition from heme-HSA (0.015 ± 0.002 and 0.013 ± 0.001 s−1, respectively), and markedly faster heme-binding kinetics (kfast ≈ 5−7 × 107 M−1 s−1) than apoHb and PEG-apoHb, while exhibiting only modest reductions in ferric heme affinity. SEC-HPLC, DLS, and SDS-PAGE analysis further showed that HR-MA-PEG-Hb formed a more homogeneous conjugate with a narrower molecular-weight (MW) distribution and lower polydispersity than MA-PEG-apoHb, which exhibited a broader MW distributions and greater heterogeneity. Overall, HR-MA-PEG-Hb, and to a lesser extent MA-PEG-apoHb, demonstrated the most favorable combination of structural homogeneity, physicochemical properties, heme-binding affinity, and kinetic performance, thus identifying HR-MA-PEG-Hb as the most promising candidate for the treatment of heme toxicity.
- 17 August 2026
- Published by American Chemical Society (ACS) in ACS Applied Engineering Materials
- Vol. 4 (9) , 4758-4773
Open AccessComprehensive Biophysical Characterization of Multi-Arm PEGylated Apohemoglobin as a Potential Synthetic Heme Scavenger
Cell-free heme released during hemolysis is highly toxic and pro-oxidant, necessitating the development of effective heme scavengers. In this study, four hemoglobin (Hb)-derived constructs, apohemoglobin (apoHb), linear poly(ethylene glycol) (PEG) surface conjugated apoHb (PEG-apoHb), multi-arm PEG surface conjugated apoHb (MA-PEG-apoHb), and heme-removed multi-arm PEG-Hb (HR-MA-PEG-Hb) were systematically evaluated to identify an optimal heme-scavenging candidate based on production feasibility, physicochemical characteristics, structural homogeneity, and heme-binding properties. ApoHb exhibited moderate yield (53 ± 11%), high activity (71.9 ± 7.1%), the strongest apparent ferric heme affinity (Kd,app = 10.7 ± 0.7 μM), rapid heme acquisition from heme-albumin (heme-HSA) (0.017 ± 0.0003 s−1), and fast haptoglobin (Hp) binding. However, its small hydrodynamic diameter (∼3.9 nm) suggests rapid renal clearance, limiting its potential therapeutic utility. PEG-apoHb exhibited the highest yield (82 ± 6%) and increased hydrodynamic size (10.3 ± 0.4 nm), but reduced heme-binding activity, slower heme acquisition, weaker ferric heme affinity (Kd,app = 12.6 ± 0.7 μM), accelerated heme transfer to hemopexin, and markedly diminished Hp binding. In contrast, both MA-PEG-apoHb and HR-MA-PEG-Hb exhibited larger hydrodynamic diameters (18.8 ± 1.1 and 12.1 ± 0.7 nm, respectively), reduced Hp-binding kinetics, efficient heme acquisition from heme-HSA (0.015 ± 0.002 and 0.013 ± 0.001 s−1, respectively), and markedly faster heme-binding kinetics (kfast ≈ 5−7 × 107 M−1 s−1) than apoHb and PEG-apoHb, while exhibiting only modest reductions in ferric heme affinity. SEC-HPLC, DLS, and SDS-PAGE analysis further showed that HR-MA-PEG-Hb formed a more homogeneous conjugate with a narrower molecular-weight (MW) distribution and lower polydispersity than MA-PEG-apoHb, which exhibited a broader MW distributions and greater heterogeneity. Overall, HR-MA-PEG-Hb, and to a lesser extent MA-PEG-apoHb, demonstrated the most favorable combination of structural homogeneity, physicochemical properties, heme-binding affinity, and kinetic performance, thus identifying HR-MA-PEG-Hb as the most promising candidate for the treatment of heme toxicity.
- Open Access
- 5 July 2026
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 123 (9) , 2229-2237
Hemopexin Purification From Human Cohn Fraction IV Paste and Its Biophysical Characterization and Functional Evaluation in Sickle Cell Disease Mice
Hemopexin (Hpx) is an acute phase plasma protein that is responsible for sequestration and removal of cell‐free heme with very high affinity (K d < 1 pM). Hpx expression in liver cells is induced following an inflammatory event such as severe hemolysis. Therefore, plasma Hpx has potential clinical relevance due to its' ability to bind free heme, thus reducing lipid peroxidation and activation of inflammatory pathways in genetic anemias, such as sickle cell disease (SCD). This provides the rationale for purifying Hpx at high purity and at large scale. Starting from human Cohn fraction IV, we purified a protein cocktail using tangential flow filtration for use in this study as the starting material for purification of Hpx. Hpx was purified from the protein cocktail using immobilized metal ion affinity chromatography. SDS‐PAGE and densitometric analysis showed that Hpx was purified to homogeneity and was approximately 99% pure. To gain further insight into Hpx activity and its' ligand binding properties, we employed comparative biophysical techniques such as UV‐visible, circular dichroism, electron paramagnetic resonance and stopped flow spectroscopy. Finally we evaluated Hpx in a mouse model of SCD to test the ability of the novel material to attenuate tissue iron accumulation.
- 5 July 2026
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 123 (9) , 2229-2237
Open AccessHemopexin Purification From Human Cohn Fraction IV Paste and Its Biophysical Characterization and Functional Evaluation in Sickle Cell Disease Mice
Hemopexin (Hpx) is an acute phase plasma protein that is responsible for sequestration and removal of cell‐free heme with very high affinity (K d < 1 pM). Hpx expression in liver cells is induced following an inflammatory event such as severe hemolysis. Therefore, plasma Hpx has potential clinical relevance due to its' ability to bind free heme, thus reducing lipid peroxidation and activation of inflammatory pathways in genetic anemias, such as sickle cell disease (SCD). This provides the rationale for purifying Hpx at high purity and at large scale. Starting from human Cohn fraction IV, we purified a protein cocktail using tangential flow filtration for use in this study as the starting material for purification of Hpx. Hpx was purified from the protein cocktail using immobilized metal ion affinity chromatography. SDS‐PAGE and densitometric analysis showed that Hpx was purified to homogeneity and was approximately 99% pure. To gain further insight into Hpx activity and its' ligand binding properties, we employed comparative biophysical techniques such as UV‐visible, circular dichroism, electron paramagnetic resonance and stopped flow spectroscopy. Finally we evaluated Hpx in a mouse model of SCD to test the ability of the novel material to attenuate tissue iron accumulation.
- Open Access
- 2 June 2026
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 14 (24) , 7528-7542
Hemoglobin-based oxygen carriers with antioxidant properties
Hemoglobin (Hb)-based oxygen carriers (HBOCs) are being investigated as therapeutics for the treatment of hemorrhagic shock, when red blood cells (RBCs) are unavailable. Researchers have investigated different techniques to impart antioxidant properties to HBOCs, in order to mitigate oxidative damage observed after hemorrhagic shock resuscitation. In our previous work, we have investigated the coating of Hb with polydopamine (PDA) and have shown that PDA-coated Hb exhibits antioxidant properties while retaining its oxygen transport properties. Since the PDA coating is biodegradable and cell-free Hb in circulation is toxic, in our current study, we explore PDA coating of tense (T-) and relaxed (R-) state polymerized human hemoglobin (PolyHb). Similar to our previous study on PDA coating of CO-bound human Hb, CO binding of T- and R-state PolyHb significantly reduced metHb formation of the PDA coated PolyHb. PDA coating of PolyHb resulted in enhanced antioxidant properties of PDA–PolyHb as measured by the reducing power, radical scavenging, ferryl oxidation, and catalase activity. T-state PolyHb demonstrated moderate changes in O2 transport properties after PDA coating, with both T- and R-state PolyHb exhibiting higher auto-oxidation rates after PDA coating. A slight increase in hydrodynamic diameter and a moderate decrease in thermal stability for both PDA-coated PolyHbs were observed compared to the precursor PolyHbs. T- and R-state PDA-coated PolyHb show promise as potential oxygen carriers with antioxidant properties, yet further optimization is needed to limit changes in oxygen transport properties.
- 2 June 2026
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 14 (24) , 7528-7542
Open AccessHemoglobin-based oxygen carriers with antioxidant properties
Hemoglobin (Hb)-based oxygen carriers (HBOCs) are being investigated as therapeutics for the treatment of hemorrhagic shock, when red blood cells (RBCs) are unavailable. Researchers have investigated different techniques to impart antioxidant properties to HBOCs, in order to mitigate oxidative damage observed after hemorrhagic shock resuscitation. In our previous work, we have investigated the coating of Hb with polydopamine (PDA) and have shown that PDA-coated Hb exhibits antioxidant properties while retaining its oxygen transport properties. Since the PDA coating is biodegradable and cell-free Hb in circulation is toxic, in our current study, we explore PDA coating of tense (T-) and relaxed (R-) state polymerized human hemoglobin (PolyHb). Similar to our previous study on PDA coating of CO-bound human Hb, CO binding of T- and R-state PolyHb significantly reduced metHb formation of the PDA coated PolyHb. PDA coating of PolyHb resulted in enhanced antioxidant properties of PDA–PolyHb as measured by the reducing power, radical scavenging, ferryl oxidation, and catalase activity. T-state PolyHb demonstrated moderate changes in O2 transport properties after PDA coating, with both T- and R-state PolyHb exhibiting higher auto-oxidation rates after PDA coating. A slight increase in hydrodynamic diameter and a moderate decrease in thermal stability for both PDA-coated PolyHbs were observed compared to the precursor PolyHbs. T- and R-state PDA-coated PolyHb show promise as potential oxygen carriers with antioxidant properties, yet further optimization is needed to limit changes in oxygen transport properties.
- Open Access
- 27 April 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 199, 119439
Sex determines cardiac and renal Vulnerability to chronic hemoglobin toxicity
- 27 April 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 199, 119439
Open AccessSex determines cardiac and renal Vulnerability to chronic hemoglobin toxicity
- Open Access
- 16 March 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (6) , 2082-2094
Hemoglobin binders reduce inflammation and tissue injury from hemolysis in venovenous extracorporeal circulation
This study investigated the pathophysiological effects of cell-free hemoglobin (Hb) generated by mechanical hemolysis during venovenous extracorporeal circulation (VVECC). We hypothesized that Hb scavenger protein constructs that bind Hb, heme, and iron could attenuate end-organ injury caused by intravascular hemolysis during VVECC. Scavenger constructs consisted of an apohemoglobin-haptoglobin (apoHb-Hp) complex designed to bind Hb and heme, as well as a separate preparation of haptoglobin, albumin, hemopexin, and transferrin, termed the protein cocktail. To test the hypothesis, Golden Syrian hamsters were instrumented with dorsal window chambers and catheters, and VVECC was maintained for a total of 2 hours, with a maximum flow rate equivalent to 50% of the animal’s cardiac output. VVECC circuits were primed with either 2 binding materials, apoHb-Hp and the protein cocktail, or a control solution of 5% human serum albumin (HSA). Microvascular Hb oxygen saturation in arterioles (saO2) and venules (svO2) were studied. All groups displayed a significant decrease in saO2 and svO2 at maximum VVECC when compared with baseline, whereas statistically significant changes between treatment groups showed no consistent trend. The protein cocktail bound 24% of cell-free Hb, whereas the apoHb-Hp bound 66% of cell-free Hb. In addition, markers of renal damage and inflammation, such as plasma creatinine, urinary NGAL (neutrophil gelatinase-associated lipocalin), 4-HNE (4-hydroxynonenal), and KIM-1 (kidney injury molecule 1), were significantly reduced in both Hb scavenger groups compared with those in the HSA control group. Results from this study suggest that Hb, heme, and iron scavenging solutions used to prime VVECC circuits support organ function.
- 16 March 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (6) , 2082-2094
Open AccessHemoglobin binders reduce inflammation and tissue injury from hemolysis in venovenous extracorporeal circulation
This study investigated the pathophysiological effects of cell-free hemoglobin (Hb) generated by mechanical hemolysis during venovenous extracorporeal circulation (VVECC). We hypothesized that Hb scavenger protein constructs that bind Hb, heme, and iron could attenuate end-organ injury caused by intravascular hemolysis during VVECC. Scavenger constructs consisted of an apohemoglobin-haptoglobin (apoHb-Hp) complex designed to bind Hb and heme, as well as a separate preparation of haptoglobin, albumin, hemopexin, and transferrin, termed the protein cocktail. To test the hypothesis, Golden Syrian hamsters were instrumented with dorsal window chambers and catheters, and VVECC was maintained for a total of 2 hours, with a maximum flow rate equivalent to 50% of the animal’s cardiac output. VVECC circuits were primed with either 2 binding materials, apoHb-Hp and the protein cocktail, or a control solution of 5% human serum albumin (HSA). Microvascular Hb oxygen saturation in arterioles (saO2) and venules (svO2) were studied. All groups displayed a significant decrease in saO2 and svO2 at maximum VVECC when compared with baseline, whereas statistically significant changes between treatment groups showed no consistent trend. The protein cocktail bound 24% of cell-free Hb, whereas the apoHb-Hp bound 66% of cell-free Hb. In addition, markers of renal damage and inflammation, such as plasma creatinine, urinary NGAL (neutrophil gelatinase-associated lipocalin), 4-HNE (4-hydroxynonenal), and KIM-1 (kidney injury molecule 1), were significantly reduced in both Hb scavenger groups compared with those in the HSA control group. Results from this study suggest that Hb, heme, and iron scavenging solutions used to prime VVECC circuits support organ function.
- 4 March 2026
- Published by Wolters Kluwer Health in ASAIO Journal
Acellular Hemoglobin Impairs Cardiomyocyte Excitation-Contraction Coupling
Heart failure is a significant complication of chronic intravascular hemolysis, a condition characterized by red blood cells (RBCs) breakdown, leading to the release of acellular hemoglobin (Hb) and its oxidized form, methemoglobin (MetHb), into the bloodstream. Acellular Hb promotes nitric oxide (NO) scavenging, oxidative stress, inflammation, iron overload, and functional tissue impairment. This study investigates the direct impact of Hb and MetHb on cardiomyocyte function by assessing calcium transients, fractional shortening, and reactive oxygen species (ROS) formation. The study also evaluated the effects of polymerized Hb, NO scavenging, and antioxidant therapy using N-acetylcysteine (NAC) on cardiomyocyte contractility. Our results show that acellular Hb and MetHb impair cardiomyocyte function by prolonging calcium transient half-life, reducing contractility, and increasing ROS production. Polymerization of Hb and antioxidant supplementation offered partial protection but did not fully mitigate these effects. Inhibiting NO synthase did not increase Hb toxicity, indicating that NO scavenging is not the sole toxicity pathway. These findings demonstrate that Hb-induced cardiomyocyte dysfunction involves a multifactorial mechanism, including NO scavenging, oxidative stress, and disrupted calcium dynamics. Although Hb polymerization and antioxidants offer limited protection, novel multi-target strategies are essential to address Hb toxicity in hemolytic disorders and the use of Hb-based oxygen carriers. Export
- 4 March 2026
- Published by Wolters Kluwer Health in ASAIO Journal
Acellular Hemoglobin Impairs Cardiomyocyte Excitation-Contraction Coupling
Heart failure is a significant complication of chronic intravascular hemolysis, a condition characterized by red blood cells (RBCs) breakdown, leading to the release of acellular hemoglobin (Hb) and its oxidized form, methemoglobin (MetHb), into the bloodstream. Acellular Hb promotes nitric oxide (NO) scavenging, oxidative stress, inflammation, iron overload, and functional tissue impairment. This study investigates the direct impact of Hb and MetHb on cardiomyocyte function by assessing calcium transients, fractional shortening, and reactive oxygen species (ROS) formation. The study also evaluated the effects of polymerized Hb, NO scavenging, and antioxidant therapy using N-acetylcysteine (NAC) on cardiomyocyte contractility. Our results show that acellular Hb and MetHb impair cardiomyocyte function by prolonging calcium transient half-life, reducing contractility, and increasing ROS production. Polymerization of Hb and antioxidant supplementation offered partial protection but did not fully mitigate these effects. Inhibiting NO synthase did not increase Hb toxicity, indicating that NO scavenging is not the sole toxicity pathway. These findings demonstrate that Hb-induced cardiomyocyte dysfunction involves a multifactorial mechanism, including NO scavenging, oxidative stress, and disrupted calcium dynamics. Although Hb polymerization and antioxidants offer limited protection, novel multi-target strategies are essential to address Hb toxicity in hemolytic disorders and the use of Hb-based oxygen carriers. Export
- Open Access
- 21 February 2026
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 351, 151051
Evaluation of methemoglobin and polymerized methemoglobin for detoxification of cyanide, azide, and sulfide in in vitro binding models
- 21 February 2026
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 351, 151051
Open AccessEvaluation of methemoglobin and polymerized methemoglobin for detoxification of cyanide, azide, and sulfide in in vitro binding models